Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity

Journal of Controlled Release

Volumn 170, Issue 3, 2013, Pages 460-468

  Di Mascolo, Daniele ^a,b   Lyon, Christopher J ^a   Aryal, Santosh ^a   Ramirez, Maricela R ^a   Wang, Jun ^a,c   Candeloro, Patrizio ^b   Guindani, Michele ^d   Hsueh, Willa A ^a   Decuzzi, Paolo ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b University Hospital Magna Graecia of Catanzaro   (Italy)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Inflammatory diseases; Macrophage targeting; PLGA PVA nanospheres; PPAR agonists

Indexed keywords

BIOCOMPATIBILITY; GENE EXPRESSION; GENES; MACROPHAGES; METABOLISM; NANOSPHERES; NUTRITION; PATHOLOGY;

INFLAMMATORY CONDITIONS; INFLAMMATORY DISEASE; INFLAMMATORY PROCESS; INFLAMMATORY RESPONSE; MACROPHAGE TARGETING; NUCLEAR RECEPTORS; SYSTEMIC DELIVERIES; WHITE ADIPOSE TISSUES;

DISEASES;

NANOSPHERE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYGLACTIN; POLYVINYL ALCOHOL; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE; GENE EXPRESSION; HEART FUNCTION; INFLAMMATION; LIPID DIET; LIPID METABOLISM; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PHAGOSOME; PRIORITY JOURNAL; UPREGULATION; WHITE ADIPOSE TISSUE;

INFLAMMATORY DISEASES; MACROPHAGE TARGETING; PLGA/PVA NANOSPHERES; PPARΓ AGONISTS;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MARROW CELLS; CELL LINE; CELLS, CULTURED; GENE EXPRESSION REGULATION; HEPATITIS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NANOSPHERES; OBESITY; POLYVINYL ALCOHOL; RECEPTORS, LDL; THIAZOLIDINEDIONES;

EID: 84885130620     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.012     Document Type: Article

References (40)

1. J.M. Olefsky, C.K. Glass, Macrophages, inflammation, and insulin resistance, Annu. Rev. Physiol. 72 (2010) 219-246.
2. E.S. Calay, G.S. Hotamisligil, Turning off the inflammatory, but not the metabolic, flames, Nat. Med. 19 (2013) 265-267.
3. P. Libby, M. Aikawa, Stabilization of atherosclerotic plaques: new mechanisms and clinical targets, Nat. Med. 8 (2002) 1257-1262. (Pubitemid 35373557)
4. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, C.K. Glass, Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest. 106 (2000) 523-531. (Pubitemid 30666385)
5. A.L. Hevener, J.M. Olefsky, D. Reichart, M.T. Nguyen, G. Bandyopadyhay, H.Y. Leung, M.J. Watt, C. Benner, M.A. Febbraio, A.K. Nguyen, B. Folian, S. Subramaniam, F.J. Gonzalez, C.K. Glass, M. Ricote, Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones, J. Clin. Invest. 117 (2007) 1658-1669. (Pubitemid 46871350)
6. B. Cariou, B. Charbonnel, B. Staels, Thiazolidinediones and PPARgamma agonists: time for a reassessment, Trends Endocrinol. Metab. 23 (2012) 205-215.
7. M. Lehrke, M.A. Lazar, The many faces of PPARgamma, Cell 123 (2005) 993-999.
8. J.P. Morrow, A. Katchman, N.H. Son, C.M. Trent, R. Khan, T. Shiomi, H. Huang, V. Amin, J.M. Lader, C. Vasquez, G.E. Morley, J. D'Armiento, S. Homma, I.J. Goldberg, S.O. Marx, Mice with cardiac overexpression of peroxisome proliferator-activated receptor gamma have impaired repolarization and spontaneous fatal ventricular arrhythmias, Circulation 124 (2011) 2812-2821.
9. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol. 2 (2007) 751-760. (Pubitemid 350223348)
10. S.A. Wickline, A.M. Neubauer, P.M. Winter, S.D. Caruthers, G.M. Lanza, Molecular imaging and therapy of atherosclerosis with targeted nanoparticles, J. Magn. Reson. Imaging 25 (2007) 667-680. (Pubitemid 46516717)
11. M. Ferrari, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer 5 (2005) 161-171. (Pubitemid 40314948)
12. P. Decuzzi, R. Pasqualini, W. Arap, M. Ferrari, Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26 (2009) 235-243.
13. J. Wang, J.D. Byrne, M.E. Napier, J.M. DeSimone, More effective nanomedicines through particle design, Small 7 (2011) 1919-1931.
14. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, M. Ferrari, Size and shape effects in the biodistribution of intravascularly injected particles, J. Control. Release 141 (2010) 320-327.
15. P. Decuzzi, M. Ferrari, The receptor-mediated endocytosis of nonspherical particles, Biophys. J. 94 (2008) 3790-3797.
16. J.A. Champion, S. Mitragotri, Role of target geometry in phagocytosis, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4930-4934.
17. S.E. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, J.M. DeSimone, The effect of particle design on cellular internalization pathways, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11613-11618.
18. W. Jiang, B.Y.S. Kim, J.T. Rutka, W.C.W. Chan, Nanoparticle-mediated cellular response is size-dependent, Nat. Nanotechnol. 3 (2008) 145-150. (Pubitemid 351355131)
19. E. Cohen-Sela, M. Chorny, N. Koroukhov, H.D. Danenberg, G. Golomb, A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles, J. Control. Release 133 (2009) 90-95.
20. C. Evora, I. Soriano, R.A. Rogers, K.M. Shakesheff, J. Hanes, R. Langer, Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipalmitoylphosphatidylcholine, J. Control. Release 51 (1998) 143-152. (Pubitemid 28252865)
21. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release 70 (2001) 1-20. (Pubitemid 32144788)
22. J.M. Silva, M. Videira, R. Gaspar, V. Préat, H.F. Florindo, Immune system targeting by biodegradable nanoparticles for cancer vaccines, J. Control. Release 168 (2013) 179-199.
23. R.M. Lago, P.P. Singh, R.W. Nesto, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet 370 (2007) 1129-1136. (Pubitemid 47464583)
24. B.J. Lestini, S.M. Sagnella, Z. Xu, M.S. Shive, N.J. Richter, J. Jayaseharan, A.J. Case, K. Kottke-Marchant, J.M. Anderson, R.E. Marchant, Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery, J. Control. Release 78 (2002) 235-247. (Pubitemid 34081868)
25. M.E. Lobatto, V. Fuster, Z.A. Fayad, W.J. Mulder, Perspectives and opportunities for nanomedicine in the management of atherosclerosis, Nat. Rev. Drug Discov. 10 (2011) 835-852.
26. B.J. Crielaard, T. Lammers, R.M. Schiffelers, G. Storm, Drug targeting systems for inflammatory disease: one for all, all for one, J. Control. Release 161 (2012) 225-234.
27. N. Seedher, M. Kanojia, Co-solvent solubilization of some poorly-soluble antidiabetic drugs, Pharm. Dev. Technol. 14 (2009) 185-192.
28. V.K. Jagtap, G. Vidyasagar, S. Dwivedi, Enhancement of solubility and dissolution of rosiglitazone by solid dispersion (kneading) technique, Am. J. PharmTech Res. 2 (2012) 577-588.
29. D.E. Owens III, N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 307 (2006) 93-102. (Pubitemid 41773257)
30. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, V. Preat, PLGA-based nanoparticles: an overview of biomedical applications, J. Control. Release 161 (2012) 505-522.
31. S.L.R. Ellison, T.J. Farrant, V. Barwick, Royal Society of Chemistry (Great Britain), Practical Statistics for the Analytical Scientist: A Bench Guide, 2nd ed. RSC Publishing, Cambridge, UK, 2009.
32. H. Murakami, M. Kobayashi, H. Takeuchi, Y. Kawashima, Preparation of poly(DL-lactide-co-glycolide) nanoparticles bymodified spontaneous emulsification solvent diffusion method, Int. J. Pharm. 187 (1999) 143-152. (Pubitemid 29443894)
33. A.N.F. Versypt, D.W. Pack, R.D. Braatz, Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres - a review, J. Control. Release 165 (2012) 29-37.
34. R.A. Siegel, M.J. Rathbone, Overview of controlled release mechanisms, Fundamentals and Applications of Controlled Release Drug Delivery, Springer, 2012, pp. 19-43.
35. J.Y. Yoo, J.M. Kim, K.S. Seo, Y.K. Jeong, H.B. Lee, G. Khang, Characterization of degradation behavior for PLGA in various pH condition by simple liquid chroma-tography method, Biomed. Mater. Eng. 15 (2005) 279-288. (Pubitemid 40991530)
36. C. Giaginis, S. Theocharis, A. Tsantili-Kakoulidou, Investigation of the lipophilic behaviour of some thiazolidinediones: relationships with PPAR-γ activity, J. Chromatogr. B 857 (2007) 181-187. (Pubitemid 47454564)
37. S.M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463-478. (Pubitemid 37237636)
38. S.Y. Park, Y.R. Cho, B.N. Finck, H.J. Kim, T. Higashimori, E.G. Hong, M.K. Lee, C. Danton, S. Deshmukh, G.W. Cline, J.J. Wu, A.M. Bennett, B. Rothermel, A. Kalinowski, K.S. Russell, Y.B. Kim, D.P. Kelly, J.K. Kim, Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver, Diabetes 54 (2005) 2514-2524. (Pubitemid 41233572)
39. R. Nagahama, T. Matoba, K. Nakano, S. Kim-Mitsuyama, K. Sunagawa, K. Egashira, Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 2427-2434.
40. C.F. Alves, N.F.S. de Melo, L.F. Fraceto, D.R. de Araújo, M.H. Napimoga, Effects of 15d-PGJ2-loaded poly(D, L-lactide-co-glycolide) nanocapsules on inflammation, Br. J. Pharmacol. 162 (2011) 623-632.